- Conditions
- Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma, Chronic Lymphocytic Leukemia
- Interventions
- CD3/CD28 Activated T cells
- Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 409–432
of 2,869
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Myeloid Malignancy
- Interventions
- azacitidine
- Drug
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Transplanted Organ Rejection
- Interventions
- FCR001
- Biological
- Lead sponsor
- Talaris Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • La Jolla, California • San Francisco, California + 14 more
- Conditions
- Non-Hodgkin Lymphoma, Hodgkin Lymphoma
- Interventions
- Etoposide, BCNU, AraC, Melphalan, Peripheral blood stem cell transplantation, G-CSF, Cyclophosphamide, Total Body Irradiation
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Epidermolysis Bullosa
- Interventions
- Palifermin, Fludarabine, Busulfan, Lorazepam, Alemtuzumab, Tacrolimus
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Chicago, Illinois • New York, New York
- Conditions
- Diagnoses That Require Stem Cell Transplant, Graft Versus Host Disease (GVHD)
- Interventions
- Maraviroc
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 5 Years to 40 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Multiple Myeloma
- Interventions
- Dexamethasone, Cyclophosphamide, Melphalan, Fludarabine, Bortezomide, Leukapheresis, Interleukin, Infusion #1, Leukapheresis #2, Infusion #2, Auto Graft
- Drug · Procedure
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia-2, High Grade Malignant Neoplasm, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts-2, Myeloid Neoplasm, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Interventions
- Cladribine, Cyclosporine, Cytarabine, Filgrastim, Fludarabine Phosphate, Allogeneic Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Melphalan, Mitoxantrone Hydrochloride, Mycophenolate Mofetil, Questionnaire Administration, Sirolimus, Total-Body Irradiation, Melphalan Hydrochloride
- Drug · Biological · Procedure + 2 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Acute Myeloid Leukemia, Measurable Residual Disease
- Interventions
- Motixafortide
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Lymphoma, Large-Cell, Diffuse
- Interventions
- Rituximab, Etoposide, Carboplatine, Ifosfamide + Mesna, Cisplatine, Cytosine Arabinoside, Dexamethasone, Autologous Stem Cell Transplantation, BCNU, Cytarabine, Melphalan
- Drug · Procedure
- Lead sponsor
- Lymphoma Study Association
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 481 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- Interventions
- Enasidenib
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • Columbus, Ohio
- Conditions
- MDS
- Interventions
- Allogeneic Hematopoietic Cell Transplant, Hypomethylating Therapy / Best Supportive Care
- Procedure
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 384 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 37
- States / cities
- Duarte, California • Stanford, California • Gainesville, Florida + 28 more
- Conditions
- Acute Myeloid Leukemia, Pediatric AML
- Interventions
- Idarubicin Hydrochloride, Fludarabine, Cytarabine (Ara-C), Venetoclax, Etoposide, Asparaginase Erwinia Chrysanthemi (recombinant), Intrathecal triple, SOC
- Drug · Other
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 1 Month to 30 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Viral Infection
- Interventions
- HLA-matched VSTs
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Neoplasms, Hematologic Neoplasms, Healthy Volunteers
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 2 Years to 100 Years
- Enrollment
- 6,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Sickle Cell Disease
- Interventions
- Haploidentical Transplant, Alemtuzumab, Total Body Irradiation, Cyclophosphamide, Sirolimus
- Procedure · Drug · Radiation
- Lead sponsor
- Damiano Rondelli, MD
- Other
- Eligibility
- 16 Years to 60 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Leukemia, Lymphoma, Myelodysplasia
- Interventions
- CliniMACS α/β T-Cell and CD19+ B-Cell Depleted Peripheral Blood Stem Cell Transplant
- Device
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- Up to 23 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- HIV Associated Lymphoma
- Interventions
- HST-NEETs, Bone Marrow Transplant
- Biological
- Lead sponsor
- Catherine Bollard
- NIH
- Eligibility
- 15 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 11
- States / cities
- Duarte, California • Washington D.C., District of Columbia • Tampa, Florida + 6 more
- Conditions
- Cytomegaloviral Infection, Hematopoietic and Lymphoid System Neoplasm
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, CMV pp65 Peptide-loaded Alpha-type-1 Polarized Dendritic Cell Vaccine
- Procedure · Biological
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Interventions
- filgrastim, carboplatin, cyclophosphamide, paclitaxel, topotecan hydrochloride, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2003
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Bronchiolitis
- Interventions
- Fluticasone Propionate
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- filgrastim, monoclonal antibody m170, cyclosporine, paclitaxel, peripheral blood stem cell transplantation, yttrium Y 90 monoclonal antibody m170
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Fanconi Anemia
- Interventions
- Cyclophosphamide, Fludarabine, Total body irradiation (TBI)
- Drug · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2001 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases
- Interventions
- anti-thymocyte globulin, filgrastim, busulfan, cyclophosphamide, cyclosporine, fludarabine phosphate, melphalan, methylprednisolone, umbilical cord blood transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- Up to 17 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 25
- States / cities
- Duarte, California • Los Angeles, California • Orange, California + 20 more